This precision is what makes them a powerful tool in anti-aging and regenerative medicine
On May 2, 2026, The Lancet published a randomized, double-blind, placebo-controlled trial (Klausen et al., Copenhagen University Hospital) testing once-weekly semaglutide 2.4 mg in 108 treatment-seeking adults with moderate to severe alcohol use disorder and comorbid obesity
These new insights will help develop better diagnostic approaches that identify clinically important subsets of patients for whom the natural history of disease and response to treatment are predictable
Building on previous work, a report found that intravitreal injection of FAC caused green AF in the mitochondria-rich PR ellipsoid and then gold AF in the rod OS, where the gold signature is consistent with increased bisretinoid all-trans-retinal (atRAL) (83)
LC3-II accumulation and p62 degradation suggest that Retatrutide promotes autophagy, potentially contributing to cancer cell death when cellular stress exceeds adaptive capacity
For ongoing photoprotection in light-sensitive use, continuous or seasonal maintenance dosing not a desensitization-driven off-cycle is the pattern the clinical literature actually documents